-Reuters
Myovant Sciences Announced European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Commission (EC) has approved the marketing authorization application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe symp